The US Senate has come together to pass a bill that aims to prevent pharma companies from filing multiple patents around biologic drugs as a way to delay biosimilar competitors.
Sanofi will invest more than €1 billion ($1.08 billion) in new bioproduction capacity at three manufacturing sites in France as part of a €3.5 billion programme in the cou
Roche is set to raise $1.2 billion from the sale of a US biologics manufacturing facility to Swiss contract development and manufacturing organisation (CDMO) Lonza, part o
Pharmaceutical drugs have seen a seismic shift over the past ten years, moving away from chemically synthesised drugs to focus more on a new class of biological drugs (biologics).<
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh